Implementing a Managed Entry Agreement Framework in Cyprus

References

• Petrou P. The 2019 introduction of the new National Healthcare System in Cyprus. Health Policy; 2021; p. 284–289.
   Google Scholar
• Theodorou M, Charalambous C, Petrou C, et al. Cyprus: health system review Health Syst Transit. 2012; 14(6):1–128. PMID: 23149260.
   PubMedGoogle Scholar
• OECD/EU. Health at a glance: Europe 2018: State of Health in the EU cycle. Paris: OECD Publishing; 2018.
   Google Scholar
• Petrou P, Talias MA. Tendering for pharmaceuticals as a reimbursement tool in the Cyprus Public Health Sector. Health Policy Technol. 2014;3(3):167–175. doi: 10.1016/j.hlpt.2014.04.003
   Web of Science ®Google Scholar
• Nina Z, Manuel Alexander H. PPRI Pharma Brief: Cyprus 2021. Pharmaceutical pricing and reimbursement information. Vienna: Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute; 2021.
   Google Scholar
• Petrou P. Global budget for Cyprus’ national health system: the promised land or a no man’s land? 2016. Value Health Reg Issues. 2016;10:67–72. doi: 10.1016/j.vhri.2016.07.007
   PubMedGoogle Scholar
• Efthymiadou O, Kanavos P. Impact of managed entry agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries. BMC Health Serv Res. 2022;22(1). doi: 10.1186/s12913-022-08437-w
   PubMed Web of Science ®Google Scholar
• Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels, Belgium: EMiNet; 2013.
   Google Scholar
• Fens T, Postma M. Innovative medicines & managed entry agreements; a happy marriage? Maced Pharm Bull. 2020. doi: 10.33320/maced.pharm.bull.2020.66.03.029
   Google Scholar
• Young KE, Soussi I, Toumi M. The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. J Mark Access Health Policy. 2017 Sep 3;5(1):1369817. doi: 10.1080/20016689.2017.1369817
   PubMedGoogle Scholar
• Hass EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819–1829. Epub 2021 May 5. doi: 10.1016/S0140-6736(21)00947-8
   PubMed Web of Science ®Google Scholar
• Fens T, van Puijenbroek EP, Postma MJ. Efficacy, safety, and economics of innovative medicines: the role of multi-criteria decision analysis and managed entry agreements in practice and policy. Front Med Technol. 2021 Apr 28;3:629750. PMID: 35047908; PMCID: PMC8757864. doi: 10.3389/fmedt.2021.629750
   PubMedGoogle Scholar
• Petrou P, Talias MA. Price determinants of the tendering process for pharmaceuticals in the Cyprus market. Value Health Reg Issues. 2015 Sep;7:67–73. doi: 10.1016/j.vhri.2015.09.001
   PubMedGoogle Scholar
• Part IV — EStablishment of committees. 89(Ι)/2001, Law. 2001. Official Gazette EU Par. Ι(Ι)
   Google Scholar
• Akehurst RL, Abadie E, Renaudin N, et al. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017 Jan;20(1):67–76. doi: 10.1016/j.jval.2016.08.725
   PubMed Web of Science ®Google Scholar
• Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. Pharmacoecon Open. 2022 May;6(3):315–328. doi: 10.1007/s41669-021-00311-5
   PubMed Web of Science ®Google Scholar
• Kani C, Kourafalos V, Litsa P. Current environment for introducing health technology assessment in greece. Int J Technol Assess Health Care. 2017 Jan;33(3):396–401. doi: 10.1017/S0266462317000629
   PubMed Web of Science ®Google Scholar
• Cairns J, Maynou-Pujolras L, Miners A. Organisational issues for building Health-Technology Assessment (HTA) capacity in cyprus. London: London School of Hygiene and Tropical Medicine (LSHTM); 2014.
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009 Jun;12(4):409–418. Epub 2009 Jan 12. PMID: 19900249. doi: 10.1111/j.1524-4733.2008.00489.x
   PubMed Web of Science ®Google Scholar
• Barnsley P, Cubi-Molla P, Fischer A, Towse A. Transferability of HTA. Manila: Health Technology Assesment International; 2014.
   Google Scholar
• Vogler S, Haasis MA, van den Ham R, et al. European collaborations on medicine and vaccine procurement. Bull World Health Organ. 2021 Oct 1;99(10):715–721. doi: 10.2471/BLT.21.285761
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices–budget impact analysis. Value Health. 2007 Sep;10(5):336–347. PMID: 17888098. doi: 10.1111/j.1524-4733.2007.00187.x
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014 Jan;17(1):5–14. doi: 10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• Baltussen RMPM, Adam T, Tan-Torres Edejer T, et al.; World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis/edited by T. Tan-Torres Edejer ‎et al‎. World Health Org. 2003.
   Google Scholar
• McDougall JA, Furnback WE, Wang BCM, et al. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy. 2020 Feb 15;8(1):1717030. doi: 10.1080/20016689.2020.1717030
   PubMedGoogle Scholar
• Neyt M. Value-based pricing: do not throw away the baby with the bath water. PharmacoEconomics. 2018 Jan;36(1):1–3. doi: 10.1007/s40273-017-0566-5
   PubMed Web of Science ®Google Scholar
• Petrou P, Talias MA. A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer. Cost Eff Resour Alloc. 2014;12(1):12. doi: 10.1186/1478-7547-12-12
   PubMedGoogle Scholar
• Postma MJ, Parouty M, Westra TA. Accumulating evidence for the case of differential discounting. Expert Rev Clin Pharmacol. 2013 Jan;6(1):1–3. doi: 10.1586/ecp.12.73
   PubMed Web of Science ®Google Scholar
• Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health. 2003 Jul;6(Suppl 1):S1–9. doi: 10.1046/j.1524-4733.6.s1.1.x
   PubMedGoogle Scholar
• Vreman RA, Broekhoff TF, Leufkens HG, et al. Application of managed entry agreements for innovative therapies in different settings and combinations: a feasibility analysis. Int J Environ Res Public Health. 2020 Nov 10;17(22):8309. doi: 10.3390/ijerph17228309
   PubMed Web of Science ®Google Scholar
• Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015 Jan;8(1):77–94. doi: 10.1586/17512433.2015.990380
   PubMed Web of Science ®Google Scholar
• Cox EM, Edmund AV, Kratz E, et al. Regulatory affairs 101: introduction to expedited regulatory pathways. Clin Transl Sci. 2020 May;13(3):451–461.
   PubMed Web of Science ®Google Scholar
• Antoñanzas F, Terkola R, Postma M. The value of medicines: a crucial but vague concept. PharmacoEconomics. 2016;34(12):1227–1239. doi: 10.1007/s40273-016-0434-8
   PubMed Web of Science ®Google Scholar
• Dabbous M, Chachoua L, Caban A, et al. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020 Apr;23(4):425–433.
   PubMed Web of Science ®Google Scholar
• Xoxi E, Rumi F, Kanavos P, et al. A proposal for value-based managed entry agreements in an environment of technological change and economic challenge for publicly funded healthcare systems. Front Med Technol. 2022;4. doi: 10.3389/fmedt.2022.888404.
   Google Scholar
• Annemans L, Aymé S, Le Cam Y, et al. Recommendations from the European Working Group for value assessment and funding processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017 Mar 10;12(1):50. doi: 10.1186/s13023-017-0601-9
   PubMedGoogle Scholar
• Petrou P, European Observatory on Health Systems and Policies. Financial crisis as a reform mediator in Cyprus’s health services. Eurohealth 2014;20(4):35–38. World Health Organization. Regional Office for Europe.
   Google Scholar
• Wenzl M, Chapman S, Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward, 2019, OECD, Directorate for Employment, Labour and Social Affairs, Health Division
   Google Scholar
• Jørgensen J, Kefalas P. Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test. J Mark Access Health Policy. 2017 Jul 31;5(1):1355203. doi: 10.1080/20016689.2017.1355203
   PubMedGoogle Scholar
• Hellenic National Plan for Hepatitis C. Hellenic ministry oh health; 2017. Available from: https://www.moh.gov.gr/articles/ministry/grafeio-typoy/press-releases/4865-ethniko-sxedio-drashs-gia-thn-antimetwpish-ths-hpatitidas-c
   Google Scholar
• Papatheodoridis GV, Goulis J, Sypsa V, et al. Aiming towards hepatitis C virus elimination in Greece. Ann Gastroenterol. 2019 Jul;32(4):321–329. doi: 10.20524/aog.2019.0375
   PubMed Web of Science ®Google Scholar
• Εatwell E, Swierczyna A. Emerging voluntary cooperation between European healthcare systems: are we facing a new future? Med Access Point Care. 2019;3:3. doi: 10.1177/2399202619852317
   Google Scholar